FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886016690> ?p ?o ?g. }

• W2886016690 abstract "Granulocyte colony-stimulating factors (G-CSFs) are often administered to reduce the incidence, severity, and duration of febrile neutropenia (FN) in chemotherapy patients. Tbo-filgrastim and filgrastim-sndz represent a follow-on biologic and a biosimilar version, respectively, of the short-acting G-CSF filgrastim with comparable efficacy and safety.To estimate the budget impact of increasing use of patient-(home-) administered tbo-filgrastim and filgrastim-sndz from a U.S. payer perspective.An interactive budget impact model was developed to estimate the changes in drug cost associated with projected increases in the market share of tbo-filgrastim from 5% to 10% and of filgrastim-sndz from 10% to 12% (with a corresponding decrease in filgrastim market share from 85% to 78%) for a 1 million-member health plan among patients with nonmyeloid malignancies receiving chemotherapy with a high risk of FN. Patient self-administration at home was assumed for 20% of patients receiving short-acting G-CSF treatment; all products were purchased through the patient's pharmacy benefit and were assumed to have tier 3 formulary status with a patient copay of $54 per prescription. Base-case data were derived from publicly available resources. The total plan budget impact was calculated using a 1-year time horizon, along with the differences in per member per month and per member per year (PMPY) costs between the current and future scenarios.The effective annual per-patient drug cost to the plan totaled between $16,961 and $27,199, depending on dosage and packaging, for tbo-filgrastim; between $16,216 and $26,015 for filgrastim-sndz; and between $19,134 and $30,663 for filgrastim. The estimated total annual plan cost associated with patient-administered short-acting G-CSFs was $53,298,217 (PMPY = $53.30) in the current scenario and $52,828,832 (PMPY = $52.82) in the future scenario. Cost savings totaled $469,385 (PMPY = $0.48). The model was most sensitive to changes in the percentage of patients self-administering G-CSF at home and to the wholesale acquisition cost for filgrastim.The effective annual plan per-patient drug costs for tbo-filgrastim and filgrastim-sndz were 11% and 15% lower than filgrastim, respectively. The present analysis estimated an annual U.S. health plan cost savings approaching $0.5 million following increases in market shares of approximately 5% for tbo-filgrastim and 2% for filgrastim-sndz.This study was sponsored by Teva Branded Pharmaceutical Products R & D, which participated in the study design, data interpretation and analysis, the writing of the report, and the decision to submit. Aventine Consulting received consulting fees from Teva Pharmaceuticals and developed the cost model and provided data analysis support. Trautman and James are employed by Aventine Consulting. Szabo and Tang are employed by Teva Pharmaceuticals." @default.
• W2886016690 created "2018-08-22" @default.
• W2886016690 creator A5012477910 @default.
• W2886016690 creator A5055816257 @default.
• W2886016690 creator A5065779863 @default.
• W2886016690 creator A5085436731 @default.
• W2886016690 date "2019-01-01" @default.
• W2886016690 modified "2023-09-25" @default.
• W2886016690 title "Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective" @default.
• W2886016690 cites W116519768 @default.
• W2886016690 cites W1506645980 @default.
• W2886016690 cites W1546909751 @default.
• W2886016690 cites W1828514487 @default.
• W2886016690 cites W1944560152 @default.
• W2886016690 cites W1964736588 @default.
• W2886016690 cites W1964870221 @default.
• W2886016690 cites W1966522763 @default.
• W2886016690 cites W1969787209 @default.
• W2886016690 cites W1969840975 @default.
• W2886016690 cites W1977123599 @default.
• W2886016690 cites W1979101648 @default.
• W2886016690 cites W1996429338 @default.
• W2886016690 cites W2013617412 @default.
• W2886016690 cites W2024933507 @default.
• W2886016690 cites W2026417873 @default.
• W2886016690 cites W2042418092 @default.
• W2886016690 cites W2043473318 @default.
• W2886016690 cites W2055543087 @default.
• W2886016690 cites W2057783437 @default.
• W2886016690 cites W2065849727 @default.
• W2886016690 cites W2069021113 @default.
• W2886016690 cites W2074454485 @default.
• W2886016690 cites W2077781144 @default.
• W2886016690 cites W2083336892 @default.
• W2886016690 cites W2091900888 @default.
• W2886016690 cites W2096288062 @default.
• W2886016690 cites W2100082529 @default.
• W2886016690 cites W2105550105 @default.
• W2886016690 cites W2106833866 @default.
• W2886016690 cites W2107028900 @default.
• W2886016690 cites W2115059455 @default.
• W2886016690 cites W2115170812 @default.
• W2886016690 cites W2117366141 @default.
• W2886016690 cites W2119679249 @default.
• W2886016690 cites W2154011558 @default.
• W2886016690 cites W2155817335 @default.
• W2886016690 cites W2164788594 @default.
• W2886016690 cites W2169403306 @default.
• W2886016690 cites W2181679255 @default.
• W2886016690 cites W2192942249 @default.
• W2886016690 cites W2335359483 @default.
• W2886016690 cites W2341557816 @default.
• W2886016690 cites W2413047870 @default.
• W2886016690 cites W2560692010 @default.
• W2886016690 cites W2571017289 @default.
• W2886016690 cites W2610097533 @default.
• W2886016690 cites W2769723270 @default.
• W2886016690 cites W2801563950 @default.
• W2886016690 cites W3048696092 @default.
• W2886016690 cites W47829030 @default.
• W2886016690 cites W192449983 @default.
• W2886016690 doi "https://doi.org/10.18553/jmcp.2018.18094" @default.
• W2886016690 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30084301" @default.
• W2886016690 hasPublicationYear "2019" @default.
• W2886016690 type Work @default.
• W2886016690 sameAs 2886016690 @default.
• W2886016690 citedByCount "5" @default.
• W2886016690 countsByYear W28860166902020 @default.
• W2886016690 countsByYear W28860166902021 @default.
• W2886016690 countsByYear W28860166902022 @default.
• W2886016690 crossrefType "journal-article" @default.
• W2886016690 hasAuthorship W2886016690A5012477910 @default.
• W2886016690 hasAuthorship W2886016690A5055816257 @default.
• W2886016690 hasAuthorship W2886016690A5065779863 @default.
• W2886016690 hasAuthorship W2886016690A5085436731 @default.
• W2886016690 hasBestOaLocation W28860166901 @default.
• W2886016690 hasConcept C100406419 @default.
• W2886016690 hasConcept C104863432 @default.
• W2886016690 hasConcept C126322002 @default.
• W2886016690 hasConcept C177713679 @default.
• W2886016690 hasConcept C194828623 @default.
• W2886016690 hasConcept C2426938 @default.
• W2886016690 hasConcept C2776694085 @default.
• W2886016690 hasConcept C2777767877 @default.
• W2886016690 hasConcept C2779171977 @default.
• W2886016690 hasConcept C512399662 @default.
• W2886016690 hasConcept C59491497 @default.
• W2886016690 hasConcept C71924100 @default.
• W2886016690 hasConcept C98274493 @default.
• W2886016690 hasConceptScore W2886016690C100406419 @default.
• W2886016690 hasConceptScore W2886016690C104863432 @default.
• W2886016690 hasConceptScore W2886016690C126322002 @default.
• W2886016690 hasConceptScore W2886016690C177713679 @default.
• W2886016690 hasConceptScore W2886016690C194828623 @default.
• W2886016690 hasConceptScore W2886016690C2426938 @default.
• W2886016690 hasConceptScore W2886016690C2776694085 @default.
• W2886016690 hasConceptScore W2886016690C2777767877 @default.
• W2886016690 hasConceptScore W2886016690C2779171977 @default.
• W2886016690 hasConceptScore W2886016690C512399662 @default.
• W2886016690 hasConceptScore W2886016690C59491497 @default.

• next